21778 Federal Register / Vol. 77, No. 70 / Wednesday, April 11, 2012 / Notices 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP): Initial Review 

The meeting announced below 

concerns Development and Testing of a 

Clinic-Based Intervention to Increase 

Dual Protection against Unintended 

Pregnancy and STDs among High Risk 

Female Teens, FOA DP12–001, initial 

review. 

In accordance with Section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the aforementioned meeting: 

Dates: Time and Date: 

11 a.m.–5 p.m., May 8, 2012 (Closed). 

Place: Teleconference. 

Status: The meeting will be closed to the 

public in accordance with provisions set 

forth in Section 552b(c)(4) and (6), Title 5 

U.S.C., and the Determination of the Director, 

Management Analysis and Services Office, 

CDC, pursuant to Public Law 92–463. 

Matters To Be Discussed: The meeting will 

include the initial review, discussion, and 

evaluation of applications received in 

response to ‘‘Development and Testing of a 

Clinic-Based Intervention to Increase Dual 

Protection against Unintended Pregnancy 

and STDs among High Risk Female Teens, 

FOA DP12–001, initial review.’’ 

Contact Person For More Information: M. 

Chris Langub, Ph.D., Scientific Review 

Officer, CDC, 4770 Buford Highway NE., 

Mailstop F–46, Atlanta, Georgia 30341, 

Telephone: (770) 488–3585. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Dated: April 1, 2012. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2012–8660 Filed 4–10–12; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Board of Scientific Counselors, Office 

of Infectious Diseases (BSC, OID) 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC), 

announces the following meeting of the 

aforementioned committee: 

TIME AND DATE: 8 a.m.–2:50 p.m., May 2, 

2012. 

PLACE: CDC, Global Communications 

Center, 1600 Clifton Road NE., Building 

19, Auditorium B3, Atlanta, Georgia 

30333. 

STATUS: Open to the public, limited only 

by the space available. 

PURPOSE: The BSC, OID, provides 

advice and guidance to the Secretary, 

Department of Health and Human 

Services; the Director, CDC; the 

Director, OID; and the Directors of the 

National Center for Immunization and 

Respiratory Diseases, the National 

Center for Emerging and Zoonotic 

Infectious Diseases, and the National 

Center for HIV/AIDS, Viral Hepatitis, 

STD, and TB Prevention, CDC, in the 

following areas: strategies, goals, and 

priorities for programs; research within 

the national centers; and overall 

strategic direction and focus of OID and 

the national centers. 

MATTERS TO BE CONSIDERED: The meeting 

will include reports from the BSC OID 

working groups, brief updates from the 

infectious disease national centers, and 

focused discussions on CDC’s safe water 

activities, immunization infrastructure, 

and sexually transmitted diseases. 

Agenda items are subject to change as 

priorities dictate. 

CONTACT PERSON FOR MORE INFORMATION: 

Robin Moseley, M.A.T., Designated 

Federal Officer, OID, CDC, 1600 Clifton 

Road NE., Mailstop D10, Atlanta, 

Georgia 30333, Telephone: (404) 639– 

4461. 

The Director, Management Analysis 

and Services Office has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities, for both the 

Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Dated: April 5, 2012. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2012–8682 Filed 4–10–12; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Submission for OMB Review; 

Comment Request 

Title: Uniform Project Description 

(UPD) Program Narrative Format for 

Discretionary Grant Application Forms. 

OMB No.: 0970–0139 

Description: The proposed 

information collection would extend the 

Administration for Children and 

Families’ (ACF) Uniform Project 

Description (UPD). The UPD provides a 

uniform grant application format for 

applicants to submit project information 

in response to ACF discretionary 

funding opportunity announcements. 

ACF uses this information, along with 

other OMB-approved information 

collections (Standard Forms), to 

evaluate and rank applications. Use of 

the UPD helps to protect the integrity of 

ACF’s award selection process. All ACF 

discretionary grant programs are 

required to use this application format. 

The application consists of general 

information and instructions; the 

Standard Form 424 series, which 

requests basic information, budget 

information, and assurances; the Project 

Description that requests the applicant 

to describe how program objectives will 

be achieved; and other assurances and 

certifications. Guidance for the content 

of information requested in the Project 

Description is found in OMB Circular 

A–102; 2 CFR, Part 215; 2 CFR, Part 225; 

2 CFR, Part 230; 45 CFR, Part 74; and 

45 CFR, Part 92. 

Respondents: Applicants to ACF 

Discretionary Funding Opportunity 

Announcements. 

ANNUAL BURDEN ESTIMATES

Instrument Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden hours 

per response 

Total 

burden hours 

ACF Uniform Project Description ..................................................................... 5,500 1 60 330,000 


wreier-aviles on DSK5TPTVN1PROD with NOTICES
Federal Register / Vol. 77, No. 70 / Wednesday, April 11, 2012 / Notices 21779 

Estimated Total Annual Burden 

Hours: 330,000 

In compliance with the requirements 

of Section 506(c)(2)(A) of the Paperwork 

Reduction Act of 1995, the 

Administration for Children and 

Families is soliciting public comment 

on the specific aspects of the 

information collection described above. 

Copies of the proposed collection of 

information can be obtained and 

comments may be forwarded by writing 

to the Administration for Children and 

Families, Office of Planning, Research 

and Evaluation, 370 L’Enfant 

Promenade SW., Washington, DC 20447, 

Attn: ACF Reports Clearance Officer. 

Email address: infocollection@acf.hhs.

gov. All requests should be identified by 

the title of the information collection. 

ACF specifically requests comments 

on: (a) Whether the proposed collection 

of information is necessary for the 

proper performance of the functions of 

the agency, including whether the 

information shall have practical utility; 

(b) the accuracy of the agency’s estimate 

of the burden of the proposed collection 

of information; (c) the quality, utility, 

and clarity of the information to be 

collected; and (d) ways to minimize the 

burden information to be collected; and 

(d) ways to minimize the burden of the 

collection of information on 

respondents, including through the use 

of automated collection techniques or 

other forms of information technology. 

Consideration will be given to 

comments and suggestions submitted 

within 60 days of this publication. 

Robert Sargis, 

Reports Clearance Officer. 

[FR Doc. 2012–8589 Filed 4–10–12; 8:45 am] 

BILLING CODE 4184–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2011–N–0221] 

Agency Information Collection 

Activities; Submission for Office of 

Management and Budget Review; 

Comment Request; Experimental 

Study on Consumer Responses to 

Labeling Statements on Food 

Packages 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing 

that a proposed collection of 

information has been submitted to the 

Office of Management and Budget 

(OMB) for review and clearance under 

the Paperwork Reduction Act of 1995 

(the PRA). 

DATES: Fax written comments on the 

collection of information by May 11, 

2012. 

ADDRESSES: To ensure that comments on 

the information collection are received, 

OMB recommends that written 

comments be faxed to the Office of 

Information and Regulatory Affairs, 

OMB, Attn: FDA Desk Officer, FAX: 

202–395–7285, or emailed to 

oira_submission@omb.eop.gov. All 

comments should be identified with the 

OMB control number 0910–New and 

title ‘‘Experimental Study on Consumer 

Responses to Labeling Statements on 

Food Packages.’’ Also include the FDA 

docket number found in brackets in the 

heading of this document. 

FOR FURTHER INFORMATION CONTACT: 

Denver Presley, II, Office of Information 

Management, Food and Drug 

Administration, 1350 Piccard Dr., PI50– 

400B, Rockville, MD 20850, 301–796– 

3793. 

SUPPLEMENTARY INFORMATION: In 

compliance with 44 U.S.C. 3507, FDA 

has submitted the following proposed 

collection of information to OMB for 

review and clearance. 

Experimental Study on Consumer 

Responses to Labeling Statements on 

Food Packages—(OMB Control Number 

0910–NEW) 

I. Background 

The Nutrition Labeling and Education 

Act requires almost all packaged foods 

to bear nutrition labeling in the form of 

the Nutrition Facts label. The law also 

allows manufacturers to provide other 

nutrition information on labels in the 

form of various types of statements, 

including claims, as long as such 

statements comply with the regulatory 

limits that govern the use of each type 

of statement. There are three types of 

claims that the food industry can 

voluntarily use on food labels: (1) 

Health claims, (2) nutrient content 

claims (e.g., ‘‘Low fat’’), and (3) 

structure/function claims (e.g., 

‘‘Calcium builds strong bones.’’). 

Although the different types of claims 

are regulated differently, they all must 

be truthful and not misleading (Ref. 1). 

With the increased public interest in 

identifying healthier foods, U.S. food 

processors have been adding nutritional 

information in the form of nutrition 

symbols to food labels in addition to 

claims. Examples of nutrition symbols 

that have been used or suggested 

include nutrient-specific disclosures 

(e.g., ‘‘Guideline Daily Amounts’’) (Ref. 

2), calorie declarations (Ref. 3), 

summary product rating (e.g., ‘‘Smart 

Spot’’) (Ref. 4), a hybrid summary 

indicator with nutrient-specific 

disclosure (e.g., ‘‘Sensible Solution: 

Good Source of Calcium, Good Sources 

of 8 Vitamins and Minerals’’) (Ref. 5), 

the Facts-Up-Front icon, with and 

without positive nutrients (Ref. 6), and 

the symbol recommended by the 

Institute of Medicine (Ref. 7). Claims 

related to non-nutritional product 

characteristics are also used in food 

labeling. The claims may feature, among 

other things, statements about how 

foods are grown or made (e.g., 

‘‘Organic’’ and ‘‘All Natural’’) or 

absence of a substance (e.g., ‘‘Glutenfree’’). 

Many consumers use claims and the 

Nutrition Facts label in food choice 

decisions (Refs. 8 through 10). While 

some products carry only a single 

labeling statement (e.g., either one claim 

or one symbol) on their packages, many 

products carry two or more labeling 

statements. In addition, on the same 

package the attributes of one statement 

may differ from those of other 

statements in terms of featured nutrient, 

type of claim, framing of statement, 

nature of statement, and presentation of 

statement. For example, a package may 

display one or more statements such as 

symbols relating to nutrition content, 

statements in words relating to the 

presence of certain nutrients, statements 

in words relating to the absence of other 

nutrients, statements in words 

describing the health benefits of 

consuming foods containing or not 

containing certain nutrients, and 

statements in words describing how the 

product was produced. Moreover, all of 

those symbols and statements are 

distributed in various places on the 

package in different font sizes and 

colors. 

There exists a large body of literature 

on the impacts of different types of 

labeling statements on consumer 

perceptions and choices of products 

(Refs. 11 and 12). The majority of the 

research, including the consumer 

research that the Agency has previously 

conducted (Refs. 13 and 14), has 

focused on single labeling statements by 

eliciting study participants’ reactions to 

variants of a given statement. An 

advantage of this research approach is 

that it helps isolate the effects of 

individual statements and avoid 

potential confounding effects caused by 

the presence of other statements. A 

disadvantage of this research approach, 

however, is that it does not necessarily 

reflect the labels consumers see in the 

marketplace. In particular, the existing 


wreier-aviles on DSK5TPTVN1PROD with NOTICES